Skin Squamous Cell Carcinoma clinical trials
44 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
- L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
- Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
- MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer
- Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
- Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
- TIL Therapy in cSCC and MCC
- Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
- Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
- Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
- Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
- A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
- A Study of VET3-TGI in Patients With Solid Tumors
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- AMT-116 in Patients With Advanced Solid Tumors
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
- SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants
- A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
- Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
- ctDNA in Cutaneous Squamous Cell Carcinoma
- Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
- Intratumoral N17350 in Advanced Solid Tumors
- Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
- Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
- Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
- Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
- A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
- Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Skin Squamous Cell Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.